Fosun Pharma Subsidiary Wins Approval for Clinical Trial of FXS0887 Tablets

Reuters
2025.12.03 09:54
portai
I'm PortAI, I can summarize articles.

Shanghai Fosun Pharmaceutical's subsidiary has received approval to conduct a clinical trial for FXS0887 tablets, aimed at treating advanced malignant solid tumors. This development marks a significant step in the company's research and development efforts.

Shanghai Fosun Pharmaceutical Subsidiary Receives Approval for Clinical Trial of FXS0887 Tablets for Advanced Malignant Solid Tumors Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251203-11942148), on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer